SecSonar.com

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Spyre Therapeutics, Inc. (SYRE) is a Biotechnology company based in US with a market capitalization of $4.4B. Free cash flow was negative at -$169.3M. This page tracks SYRE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 73 employees · IPO Apr 7, 2016

Valuation

Valuation & price

$74.92 · as of May 17, 2026 · -25.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

6.12

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$100$57.57$14.82Jul 25Dec 25Jul 26Jul 7, 25$15.30Jul 9, 25$16.55Jul 11, 25$15.69Jul 15, 25$15.31Jul 17, 25$16.89Jul 21, 25$16.35Jul 23, 25$17.81Jul 25, 25$17.79Jul 29, 25$16.77Jul 31, 25$16.97Aug 4, 25$16.16Aug 6, 25$15.96Aug 11, 25$15.25Aug 13, 25$17.40Aug 15, 25$16.95Aug 19, 25$16.11Aug 21, 25$16.78Aug 25, 25$16.58Aug 27, 25$17.14Aug 29, 25$16.49Sep 3, 25$16.81Sep 5, 25$17.00Sep 9, 25$16.74Sep 11, 25$16.20Sep 16, 25$14.82Sep 18, 25$15.32Sep 22, 25$15.29Sep 24, 25$17.00Sep 26, 25$16.24Sep 30, 25$16.76Oct 2, 25$15.98Oct 6, 25$16.67Oct 8, 25$17.68Oct 10, 25$19.14Oct 14, 25$21.00Oct 16, 25$22.24Oct 21, 25$23.25Oct 23, 25$22.37Oct 27, 25$24.57Oct 29, 25$23.83Oct 31, 25$24.46Nov 4, 25$22.98Nov 6, 25$22.39Nov 10, 25$22.18Nov 12, 25$23.43Nov 14, 25$23.50Nov 18, 25$24.10Nov 20, 25$23.47Nov 25, 25$29.20Nov 28, 25$30.00Dec 2, 25$28.40Dec 4, 25$33.51Dec 8, 25$34.63Dec 10, 25$34.66Dec 12, 25$33.62Dec 16, 25$32.97Dec 18, 25$33.47Dec 22, 25$34.20Dec 24, 25$33.05Dec 29, 25$32.56Jan 2, 26$30.58Jan 6, 26$30.33Jan 8, 26$30.14Jan 12, 26$32.80Jan 14, 26$33.16Jan 16, 26$33.24Jan 21, 26$33.99Jan 23, 26$32.03Jan 27, 26$33.36Jan 29, 26$33.58Feb 2, 26$32.75Feb 4, 26$32.07Feb 9, 26$33.96Feb 11, 26$33.92Feb 13, 26$36.63Feb 18, 26$36.60Feb 20, 26$43.21Feb 24, 26$43.45Feb 26, 26$43.15Mar 2, 26$42.49Mar 4, 26$41.00Mar 6, 26$40.15Mar 10, 26$41.57Mar 12, 26$40.41Mar 17, 26$43.95Mar 19, 26$42.31Mar 23, 26$42.76Mar 25, 26$45.68Mar 27, 26$47.31Mar 31, 26$50.44Apr 2, 26$47.58Apr 7, 26$51.20Apr 9, 26$51.77Apr 13, 26$63.27Apr 15, 26$68.99Apr 17, 26$73.01Apr 22, 26$73.00Apr 24, 26$69.67Apr 28, 26$68.63Apr 30, 26$74.45May 4, 26$69.13May 6, 26$73.00May 8, 26$75.05May 12, 26$75.04May 14, 26$75.65May 18, 26$70.08May 20, 26$71.92May 22, 26$74.05May 28, 26$72.11Jun 1, 26$70.54Jun 3, 26$73.52Jun 5, 26$73.65Jun 9, 26$76.44Jun 11, 26$80.77Jun 15, 26$83.58Jun 17, 26$87.49Jun 22, 26$100.32Jun 24, 26$86.24Jun 26, 26$87.89Jul 2, 26$86.63
$14.8252-week range$100.32
Loading valuation history…

Fundamentals

Key fundamentals

$4.4B

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$169.3M

Free cash flow (USD)

-$756.5M

Net debt

Net cash position

635.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.6MFY 2017$5.2MFY 2018$3.9MFY 2019$0.00FY 2020$0.00FY 2021$18.7MFY 2022$2.3MFY 2023$886.0KFY 2024$0.00FY 2025$0.00
$4.6M$0

Free cash flow by year

2016 → 2025

FY 2016$-19.1MFY 2017$-25.2MFY 2018$-32.6MFY 2019$-67.2MFY 2020$-80.1MFY 2021$-54.3MFY 2022$-80.2MFY 2023$-99.9MFY 2024$-157.4MFY 2025$-169.3M
-$19.1M-$169.3M

Gross margin by year

2021 → 2023

FY 2021100.0%FY 2022100.0%FY 2023100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

13

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.3M · 10b5-1 PlanTurtle Cameron · Director, Chief Executive Officer · $1.3MJul 2, 2026Filing
  • Insider sellInsider Sell $731K · 10b5-1 PlanSloan Sheldon · Chief Medical Officer · $730.9KJul 2, 2026Filing
  • Insider sellInsider Sell $658K · 10b5-1 PlanBurrows Scott L · Chief Financial Officer · $658KJul 2, 2026Filing
  • Insider sellInsider Sell $1.3MBurrows Scott L · Chief Financial Officer · $1.3MJun 26, 2026Filing
  • FinancingSecurities RegistrationJun 26, 2026Filing
  • Insider sellInsider Sell $399.7MFairmount Funds Management LLC · Director · $399.7MJun 23, 2026Filing
  • Insider sellInsider Sell $2.0M · 10b5-1 PlanHENDERSON MICHAEL THOMAS · Director · $2MJun 23, 2026Filing
  • 8-K eventPhase 2 Trial ResultsJun 15, 2026Filing
  • Insider sellInsider Sell $533K · 10b5-1 PlanBurrows Scott L · Chief Financial Officer · $532.9KJun 3, 2026Filing
  • Insider sellInsider Sell $1.1M · 10b5-1 PlanTurtle Cameron · Director, Chief Executive Officer · $1.1MJun 3, 2026Filing

Questions

Frequently asked questions

What is Spyre Therapeutics, Inc.'s market cap?

Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $4.4B.

What is SYRE's P/E ratio?

A meaningful P/E ratio is not available for SYRE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SYRE's price-to-book (P/B) ratio?

SYRE trades at 6.12 times book value per share.

Are insiders buying SYRE stock?

SEC Form 4 filings show no open-market insider buys at Spyre Therapeutics, Inc. in the last 90 days (13 sells).

Same arena

Related companies in Biotechnology

TVTX

Travere Therapeutics, Inc.

$4.4B

XENE

Xenon Pharmaceuticals Inc.

$4.3B

LGND

Ligand Pharmaceuticals Incorporated

$4.7B

CAI

Caris Life Sciences, Inc.

$4.7B

NAMS

NewAmsterdam Pharma Company N.V.

$3.9B

CPRX

Catalyst Pharmaceuticals, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.